AAAAAA

   
Results: 1-25 | 26-50 | 51-51
Results: 1-25/51
Local therapy for prostate-specific antigen recurrence after definitive treatment
Authors: Meng, MV Carroll, PR
Citation: Mv. Meng et Pr. Carroll, Local therapy for prostate-specific antigen recurrence after definitive treatment, PROSTATE C, 4(1), 2001, pp. 20-27
Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer
Authors: Meng, MV Grossfeld, GD Williams, GH Dilworth, S Stoeber, K Mulley, TW Weinberg, V Carroll, PR Tlsty, TD
Citation: Mv. Meng et al., Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer, CLIN CANC R, 7(9), 2001, pp. 2712-2718
Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging
Authors: Mueller-Lisse, UG Swanson, MG Vigneron, DB Hricak, H Bessette, A Males, RG Wood, PJ Noworolski, S Nelson, SJ Barken, I Carroll, PR Kurhanewicz, J
Citation: Ug. Mueller-lisse et al., Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging, MAGN RES M, 46(1), 2001, pp. 49-57
Prostate cancer early detection: a clinical perspective
Authors: Grossfeld, GD Carroll, PR
Citation: Gd. Grossfeld et Pr. Carroll, Prostate cancer early detection: a clinical perspective, EPIDEMIOL R, 23(1), 2001, pp. 173-180
Overview consensus statement
Authors: Carroll, PR Fair, WR Grossfeld, GD Heston, WDW Lieberman, R Malkowicz, SB Stricker, HJ Sylvester, J Peehl, DM Meyer, F Hart, C
Citation: Pr. Carroll et al., Overview consensus statement, UROLOGY, 58(2A), 2001, pp. 1-4
Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations
Authors: Daniell, HW Chen, S Fair, WR Heston, WDW Pirani, JF Bubley, GJ Carroll, PR Gleave, ME
Citation: Hw. Daniell et al., Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations, UROLOGY, 58(2A), 2001, pp. 38-38
Discussion following Dr. Martin E. Gleave's presentation
Authors: Lieberman, R Gleave, ME Carroll, PR Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49
Discussion following Dr. Don W. W. Newling's presentation
Authors: Fair, WR Newling, DWW Carroll, PR Trachtenberg, J Daniell, HW
Citation: Wr. Fair et al., Discussion following Dr. Don W. W. Newling's presentation, UROLOGY, 58(2A), 2001, pp. 55-55
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
Authors: Grossfeld, GD Small, EJ Lubeck, DP Latini, D Broering, JM Carroll, PR
Citation: Gd. Grossfeld et al., Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy, UROLOGY, 58(2A), 2001, pp. 56-64
Discussion following Dr. Gary D. Grossfeld's presentation
Authors: Trachtenberg, J Grossfeld, GD Lubeck, DP Bubley, GJ Carroll, PR Fair, WR Newling, DWW
Citation: J. Trachtenberg et al., Discussion following Dr. Gary D. Grossfeld's presentation, UROLOGY, 58(2A), 2001, pp. 64-64
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion
Authors: Carroll, PR D'Amico, A Malkowicz, SB Gleave, ME Bubley, GJ
Citation: Pr. Carroll et al., Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 82-82
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer
Authors: Lubeck, DP Grossfeld, GD Carroll, PR
Citation: Dp. Lubeck et al., The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer, UROLOGY, 58(2A), 2001, pp. 94-99
The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer - Discussion
Authors: Lieberman, R Lubeck, DP Trachtenberg, J Stricker, HJ Newling, DWW Fair, WR Carroll, PR
Citation: R. Lieberman et al., The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 99-100
Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer
Authors: Grossfeld, GD Chaudhary, UB Reese, DM Carroll, PR Small, EJ
Citation: Gd. Grossfeld et al., Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer, UROLOGY, 58(2), 2001, pp. 240-245
Dietary trial in prostate cancer: Early experience and implications for clinical trial design
Authors: Ornish, DM Lee, KL Fair, WR Pettengill, EB Carroll, PR
Citation: Dm. Ornish et al., Dietary trial in prostate cancer: Early experience and implications for clinical trial design, UROLOGY, 57(4A), 2001, pp. 200-201
Serum prostate-specific antigen for prostate cancer early detection: Total, free, age-stratified, or complexed?
Authors: Carroll, PR
Citation: Pr. Carroll, Serum prostate-specific antigen for prostate cancer early detection: Total, free, age-stratified, or complexed?, UROLOGY, 57(4), 2001, pp. 591-593
Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association Best Practice Policy - Part I: Definition, detection,prevalence, and etiology
Authors: Grossfeld, GD Litwin, MS Wolf, JS Hricak, H Shuler, CL Agerter, DC Carroll, PR
Citation: Gd. Grossfeld et al., Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association Best Practice Policy - Part I: Definition, detection,prevalence, and etiology, UROLOGY, 57(4), 2001, pp. 599-603
Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association Best Practice Policy - Part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up
Authors: Grossfeld, GD Litwin, MS Wolf, JS Hricak, H Shuler, CL Agerter, DC Carroll, PR
Citation: Gd. Grossfeld et al., Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association Best Practice Policy - Part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up, UROLOGY, 57(4), 2001, pp. 604-610
Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CaPSURE database
Authors: Penson, DF Schonfeld, WH Flanders, SC Henke, CJ Warolin, KL Carroll, PR Litwin, MS
Citation: Df. Penson et al., Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: Results from the CaPSURE database, UROLOGY, 57(3), 2001, pp. 499-503
Localized prostate cancer: Effect of hormone deprivation therapy measured by using combined three-dimensional H-1 MR spectroscopy and MR imaging: Clinicopathologic case-controlled study
Authors: Mueller-Lisse, UG Vigneron, DB Hricak, H Swanson, MG Carroll, PR Bessette, A Scheidler, J Srivastava, A Males, RG Cha, I Kurhanewicz, J
Citation: Ug. Mueller-lisse et al., Localized prostate cancer: Effect of hormone deprivation therapy measured by using combined three-dimensional H-1 MR spectroscopy and MR imaging: Clinicopathologic case-controlled study, RADIOLOGY, 221(2), 2001, pp. 380-390
Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor
Authors: Lubeck, DP Kim, H Grossfeld, C Ray, P Penson, DF Flanders, SC Carroll, PR
Citation: Dp. Lubeck et al., Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor, J UROL, 166(6), 2001, pp. 2281-2285
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases
Authors: Moul, JW Connelly, RR Lubeck, DP Bauer, JJ Sun, L Flanders, SC Grossfeld, GD Carroll, PR
Citation: Jw. Moul et al., Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the center for prostate disease research and cancer of the prostate strategic urologic research endeavor databases, J UROL, 166(4), 2001, pp. 1322-1327
Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
Authors: Koppie, TM Grossfeld, GD Nudell, DM Weinberg, VK Carroll, PR
Citation: Tm. Koppie et al., Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?, J UROL, 166(1), 2001, pp. 111-115
Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy
Authors: Park, S Shinohara, K Grossfeld, GD Carroll, PR
Citation: S. Park et al., Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy, J UROL, 165(5), 2001, pp. 1409-1414
Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database
Authors: Grossfeld, GD Chang, JJ Broering, JM Li, JP Lubeck, DP Flanders, SC Carroll, PR
Citation: Gd. Grossfeld et al., Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database, J UROL, 165(3), 2001, pp. 851-856
Risultati: 1-25 | 26-50 | 51-51